Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)

INTRODUCTION: Incretin-based therapies exert antihyperglycaemic effects in patients with type 2 diabetes (T2D) in a blood glucose concentration-dependent fashion. The first-in-class oral glucagon-like peptide-1 receptor agonist semaglutide has potent effects on glycaemic and weight control, but litt...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomoto, Hiroshi, Furusawa, Sho, Nakamura, Akinobu, Takeuchi, Jun, Nagai, So, Yokoyama, Hiroki, Sakuma, Ichiro, Taneda, Shinji, Kurihara, Yoshio, Aoki, Shin, Miya, Aika, Kameda, Hiraku, Cho, Kyu Yong, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119155/
https://www.ncbi.nlm.nih.gov/pubmed/35584872
http://dx.doi.org/10.1136/bmjopen-2021-056885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119155/
https://www.ncbi.nlm.nih.gov/pubmed/35584872
http://dx.doi.org/10.1136/bmjopen-2021-056885

Ejemplares similares